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Abstract
Background: Type 2 diabetes (T2D) is associated with obesity and has been shown recently to
be associated with tumors/cancer. HNF1-beta  and JAZF1  genes are associated with T2D and
prostate cancer. We have previously shown that CHOP 5'UTR-c.279T>C and +nt30C>T haplotype
variants contribute to T2D. CHOP deficiency causes obesity in mice, thus CHOP gene variants may
contribute to human obesity. Furthermore, CHOP mediates apoptosis and is implicated in cancer
pathogenesis. Hence, we aimed at identifying any potential association of CHOP 5'UTR-c.279T>C
and +nt30C>T genotypes and corresponding haplotypes with overweight condition/pre-obesity
and tumors/cancer in an Italian dataset.
Methods: We recruited from Italy 45 overweight subjects (body mass index (BMI) ³ 25) and 44
control subjects (BMI < 25) as well as 54 cases with at least one cancer or at least one tumor and
43 control subjects without tumors/cancer from the general population. We excluded allelic
departure from Hardy-Weinberg equilibrium in cases and control subjects, separately.
Results: We assessed the power to detect risk odds ratios by association tests in our datasets.
We tested the hypothesis of association of CHOP 5'UTR-c.279T>C and +nt30C>T genotypes and
haplotypes with tumors/cancer and, separately, with overweight condition. Both associations were
not significant.
Conclusion: From our study, we may conclude that CHOP 5'UTR-c.279T>C and +nt30C>T
genotypes and corresponding haplotypes are not associated with tumors/cancer and pre-obesity.
However, more studies are warranted to establish the role of CHOP variants in tumor/cancer
predisposition and in overweight condition.
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Background
Type 2 diabetes (T2D) is associated with obesity. There is
increasing evidence that T2D is associated with tumors [1]
and cancers of the pancreas [2], prostate, breast, colon,
endometrium, and liver [3]. T2D genes, such as HNF-1
beta and JAZF1, have been associated with prostate cancer
[4-6]. Thus, T2D candidate genes may not only be obesity
predisposing genes, but also tumor/cancer risk genes.
CHOP mediates apoptosis and regulates mitochondrial
gene expression, thus it may be implicated in beta cell ina-
bility to replicate as well as in insulin secretion defects.
Following up on a linkage signal in the CHOP region of
chromosome 12q13.1 in Italian T2D families, we have
previously shown that CHOP  5'UTR-c.279T>C and
+nt30C>T haplotype variants are associated with early-
onset T2D under a recessive and additive model [7]. In
addition, CHOP inhibits adipogenesis [8], thus CHOP
gene variants may contribute to insulin resistance [9,10]
and/or obesity [11]. Since CHOP is regulating pro-
grammed cell death in response to stress stimuli [12], it is
implicated in tumor/cancer development.
CHOP is involved in the pathogenesis of myxoid liposar-
coma, a rare human tumor in which a reciprocal chromo-
somal translocation creates a fusion protein consisting of
CHOP and TLS, a potent oncoprotein [13]. Other tumor-
specific fusion genes, such as EWS-CHOP and TLS/FUS-
CHOP, have been detected in solid tumors [14] and
liposarcomas [15-17]. Another rearrangement of the
CHOP  gene has been reported in myxoid liposarcoma
[18].
Our aim was to find whether there is any association of
the CHOP 5'UTR-c.279T>C and +nt30C>T genotypes and
corresponding haplotypes (the latter contributing to T2D)
[7] with body mass index (BMI) ³ 25 (hereby defined as
overweight condition/pre-obesity) and/or with tumors/
cancer in an Italian dataset.
Methods
We recruited from the general population in Italy 45 sub-
jects with BMI ³ 25 and 44 control subjects with BMI < 25
and 54 subjects with at least one cancer or at least one
tumor and 43 control subjects with no history of tumor or
cancer. We obtained the written informed consent from
each subject and the approval from the Institutional
Review Board accordingly to Helsinki Declaration guide-
lines. DNA samples were directly sequenced by PCR and
an automated fluorescence sequencer with specific prim-
ers for the CHOP 5'UTR-c.279T>C and +nt30C>T geno-
types.
We calculated via 70% power and type 1 error probability
of 0.05, detectable odds ratios for genotype association
tests in our two datasets, using the prevalence of 31.3% for
overweight condition [19] and the prevalence of 2.7% for
tumors/cancer in the Italian population [20].
Via Chi-Square test statistics, we tested the alleles for
departure from Hardy-Weinberg equilibrium (HWE) in
our two datasets in cases and control subject groups, sep-
arately.
Via the Mantel-Haenszel algorithm, we tested the CHOP
5'UTR-c.279T>C and +nt30C>T genotypes for association
with BMI ³ 25 and with tumors/cancer.
In addition, we performed model free and parametric
haplotype associations tests (dominant, recessive and
additive models) for BMI ³ 25 and for tumors/cancer,
independently (EHPLUS software) [21].
Results
Risk odds ratios of 0.248/2.943 for genotypes association
tests were detectable in the pre-obesity dataset. Risk odds
ratios of 8.210 for genotype association tests were detect-
able in the tumors/cancer dataset.
All alleles tested in each group of the two datasets of BMI
³ 25 and of tumors/cancer were not in departure from
HWE.
We did not identify in our dataset any significant and
valid association of the CHOP  5'UTR-c.279T>C and
+nt30C>T genotype variants with BMI ³ 25 (Table 1) as
well as with tumors/cancer patients (Table 2).
The parametric and non-parametric CHOP  5'UTR-
c.279T>C and +nt30C>T haplotype association tests with
BMI ³ 25 as well as with tumors/cancer were also not sig-
nificant (data not shown).
Discussion
CHOP gene encodes a C/EBP (CCAAT/enhancer binding
protein family)-homologous nuclear protein that acts as
dominant-negative inhibitor of gene transcription
through dimerization with C/EBP [22]. CHOP is impli-
cated in programmed cell death [12]. Several studies
reported CHOP gene rearrangement and/or fusion with
other genes (such as EWS-CHOP and TLS/FUS-CHOP) in
tumors/cancer [13,18].
Cellular and endoplasmic reticulum (ER) stress, occurring
in response to toxic and metabolic insult, is a powerful
inducer of CHOP [12]. ER stress down-regulates insulin
receptor signaling and triggers insulin resistance [9]. Fur-
thermore, insulin increases CHOP expression in adipocyte
cells [23], and CHOP inhibits adipocyte differentiation
[8]. Thus, CHOP deficiency may contribute to obesity
[11].Journal of Experimental & Clinical Cancer Research 2009, 28:90 http://www.jeccr.com/content/28/1/90
Page 3 of 5
(page number not for citation purposes)
Glucotoxicity induces cellular stress [24], which activates
CHOP [12]. Thus, hyperglycemia may cause CHOP-medi-
ated beta-cell apoptosis and may contribute to T2D. Inter-
estingly,  CHOP  5'UTR-c.279T>C and +nt30C>T
haplotype variants are significantly associated with early-
onset T2D under a recessive and additive model [7]. For
all the above reasons, CHOP is not only a T2D gene, but
it is also an obesity candidate gene as well as a gene poten-
tially predisposing to tumors and/or cancer. Other T2D
genes, such as HNF-1 beta and JAZF1, have already been
associated with prostate cancer [4-6]. Of note, while the
prostate cancer risk HNF-1 beta variant decreases the risk
of T2D [4], variants of JAZF1 gene are associated with
both increased risk for T2D and for prostate cancer [5,6].
However, no study has up to date investigated the suscep-
tibility role of CHOP common variants in pre-obese and
tumor/cancer patients. This is the first association study
focusing on CHOP gene variants in human genomic DNA
samples of overweight subjects and tumor/cancer cases.
In our study, we did not identify any association between
CHOP 5'UTR-c.279T>C and +nt30C>T genotype and hap-
lotype variants with pre-obesity and with tumors/cancer.
Table 1: CHOP 5'UTR-c.279T>C and +nt30C>T genotype association with overweight condition (BMI ³ 25).
Genotype 45 Cases 44 Control Subjects c2 2-t P OR 95% C.I.
5'UTRc.279T>C +- + -
TT 31 14 26 18 0.92 0.33 1.53 0.59–4.02
CT 13 32 18 26 1.41 0.23 0.59 0.22–1.55
CC 1 44 0 44 0.98 0.32 8 0.06–8
+nt30C>T
TT 0 45 0 44 NA
CT 13 32 17 27 0.94 0.33 0.65 0.24–1.71
CC 32 13 27 17 0.94 0.33 1.55 0.58–4.13
X2 = Chi-Square, 2-t P = 2-tailed p-value, OR = odds ratio,
C.I. = confidence interval
Table 2: CHOP 5'UTR-c.279T>C and +nt30C>T genotype association with tumors/cancer.
Genotype 54 Cases 43 Control Subjects c2 2-t P OR 95% C.I.
5'UTRc.279T>C +- + -
TT 35 19 27 16 0.04 0.83 1.09 0.44–2.73
CT 17 37 14 29 0.01 0.91 0.95 0.37–2.45
CC 2 52 2 41 0.05 0.81 0.79 0.08–8.28
+nt30C>T
TT 2 52 1 42 0.15 0.69 1.62 0.11–46.73
CT 17 37 16 27 0.35 0.55 0.78 0.31–1.96
CC 35 19 26 17 0.19 0.66 1.20 0.48–2.99
X2 = Chi-Square, 2-t P = 2-tailed p-value, OR = odds ratio,
C.I. = confidence intervalJournal of Experimental & Clinical Cancer Research 2009, 28:90 http://www.jeccr.com/content/28/1/90
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If the CHOP gene variants tested were to contribute to
overweight condition and/or tumors/cancer with a mod-
est size effect, our datasets are too small to detect such
effects. However, we could at least exclude in the current
study a CHOP 5'UTR-c.279T>C and +nt30C>T variant risk
effect of about 3 for pre-obesity and of about 8 for tumors/
cancer.
Conclusion
In summary, we conclude that CHOP  5'UTR-c.279T>C
and +nt30C>T variants, both at genotype and at haplo-
type level, are not contributing to the overweight condi-
tion and tumors/cancer in our dataset. However, other
studies are warranted to further exclude the role of any
other CHOP variants in obesity and in tumor/cancer pre-
disposition. Since obesity is a preventable associated fac-
tor in several tumors/cancer [25] and in other co-
morbidities [26], and, since tumors and cancer may be
prevented and/or diagnosed at an earlier stage, genetic
studies to identity overweight risk predisposition as well
as tumors/cancer risk susceptibility should be further per-
formed to guide disease prediction and prevention.
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